
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher Corporation has demonstrated a strong upward trend in performance obligations, increasing from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, indicating robust demand for its products and services. The company is optimistic about a 4.5% growth ramp in the Life Sciences segment for 4Q25, driven by favorable comparisons in Genomics and supportive performance in the China market alongside new product launches. Additionally, the company's service offerings, particularly in Cepheid Respiratory, are expected to generate significant revenue, with projections of $300-350 million in 3Q25 and $450-500 million in 4Q25, showcasing a strong recovery trajectory.
Bears say
Danaher has experienced a decline in its anticipated revenue recognition, with 46% of its second-quarter 2025 obligations expected to be recognized as revenue within the next 12 months, a decrease from 48% in the previous quarter. This decline, coupled with significant risks such as geopolitical disruptions and the uncertain recovery of key high-growth end-markets like China, raises concerns about the company's ability to maintain consistent performance. Additionally, the slightly below-expectations revenue guidance for its Biotechnology and Life Sciences segment further contributes to the negative outlook, as it suggests challenges in meeting growth targets amid lingering macroeconomic headwinds.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares